Ironwood Pharmaceuticals (IRWD)
(Delayed Data from NSDQ)
$4.05 USD
-1.96 (-32.61%)
Updated Aug 8, 2024 04:00 PM ET
After-Market: $4.04 -0.01 (-0.25%) 7:48 PM ET
5-Strong Sell of 5 5
C Value B Growth B Momentum B VGM
Brokerage Reports
Ironwood Pharmaceuticals, Inc. [IRWD]
Reports for Purchase
Showing records 1001 - 1020 ( 1026 total )
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Q2:12 Financial Update - Awaiting September PDUFA - Reiterate UNDERPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
LIFE SCIENCES: The Week Ahead in Life Sciences - Upcoming Events for the Week of July 8
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of July 1
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
LIFE SCIENCES: The Week Ahead in Life Sciences - Upcoming Events for the Week of May 27
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
LIFE SCIENCES-The Week Ahead in Life Sciences - Upcoming Events for the Week of May 6
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Q1:12 Cash Burn Higher Than Expected, We Continue to View Large Financing as Inevitable
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of April 29
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Downgrading to UNDERPERFORM; Updated Launch Expenses Leads to Significant Anticipated Funding Gap
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Acquires Rights to BNC210 - A Potential Blockbuster for Anxiety and Depression
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Biotechnology/Biopharmaceuticals/BioDefense: October 2011 Potential Milestones & Key Events - Monthly Update.
Provider: WEDBUSH SECURITIES INC.
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Partner Almirall Submits MAA in the EU for Linaclotide, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
Q2:11 EPS Uneventful, Next Up Is EU Linaclotide Submission
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
August 2011 Potential Milestones & Key Events - Monthly Update
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Ironwood Pharmaceuticals, Inc.
Industry: Medical - Drugs
We initiate coverage of Ironwood with a Hold rating
Provider: DUNCAN-WILLIAMS, INC.
Analyst: RIVKIND I